奥法妥木单抗——慢性淋巴细胞白血病患者的有效治疗选择。
Ofatumumab - a valid treatment option for chronic lymphocytic leukemia patients.
作者信息
AlDallal Salma M
机构信息
Haematology Laboratory, Amiri Hospital, Kuwait City, Kuwait.
出版信息
Ther Clin Risk Manag. 2017 Jul 20;13:905-907. doi: 10.2147/TCRM.S140023. eCollection 2017.
Abstract
Ofatumumab Arzerra is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro complement-dependent cytotoxicity and antibody-dependent, cell-mediated cytotoxicity. The humanized anti-CD20 monoclonal antibody has been approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia patients. This article summarizes this antibody's therapeutic effect on chronic lymphocytic leukemia.
摘要
奥法木单抗（Arzerra）是一种人源单克隆抗体，它通过激活体外补体依赖性细胞毒性和抗体依赖性细胞介导的细胞毒性，诱导一组肿瘤B细胞系和原发性肿瘤细胞的杀伤。这种人源化抗CD20单克隆抗体已获美国食品药品监督管理局批准用于治疗慢性淋巴细胞白血病患者。本文总结了该抗体对慢性淋巴细胞白血病的治疗效果。
相似文献
1
Ofatumumab - a valid treatment option for chronic lymphocytic leukemia patients.奥法妥木单抗——慢性淋巴细胞白血病患者的有效治疗选择。
Ther Clin Risk Manag. 2017 Jul 20;13:905-907. doi: 10.2147/TCRM.S140023. eCollection 2017.
2
Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells.补体因子 H 衍生的短串联重复 18-20 增强奥法木单抗对慢性淋巴细胞白血病细胞的补体依赖性细胞毒性。
Haematologica. 2013 Dec;98(12):1939-47. doi: 10.3324/haematol.2013.089615. Epub 2013 Jul 12.
3
Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.奥法妥木单抗治疗新诊断和复发/难治性慢性淋巴细胞白血病。
Expert Rev Anticancer Ther. 2011 Feb;11(2):151-60. doi: 10.1586/era.10.223.
4
Ofatumumab: a novel monoclonal anti-CD20 antibody.奥法木单抗：一种新型抗CD20单克隆抗体。
Pharmgenomics Pers Med. 2010;3:51-9. doi: 10.2147/pgpm.s6840. Epub 2010 May 10.
5
Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.序贯使用奥法妥木单抗和来那度胺治疗复发难治性慢性淋巴细胞白血病和小淋巴细胞淋巴瘤。
Leuk Lymphoma. 2015 Mar;56(3):645-9. doi: 10.3109/10428194.2014.935369.
6
Role of ofatumumab in treatment of chronic lymphocytic leukemia.奥法木单抗在慢性淋巴细胞白血病治疗中的作用。
你提供的原文中“Role of ofatumumab”多了一个“of”。
J Blood Med. 2011;2:71-7. doi: 10.2147/JBM.S13063. Epub 2011 May 2.
7
Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.奥法妥木单抗作为未经治疗的慢性淋巴细胞白血病的一线治疗药物。
Future Oncol. 2014 May;10(7):1147-55. doi: 10.2217/fon.14.73.
8
Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.奥法妥珠单抗，一种新型抗 CD20 单克隆抗体，用于治疗 B 细胞恶性肿瘤。
J Clin Oncol. 2010 Jul 20;28(21):3525-30. doi: 10.1200/JCO.2010.27.9836. Epub 2010 May 10.
9
Ofatumumab for the treatment of chronic lymphocytic leukemia.奥法木单抗用于治疗慢性淋巴细胞白血病。
Expert Rev Hematol. 2015 Jun;8(3):265-72. doi: 10.1586/17474086.2015.1037736. Epub 2015 Apr 16.
10
Ofatumumab, a human anti-CD20 monoclonal antibody.奥法妥木单抗，一种人源抗 CD20 单克隆抗体。
Expert Opin Biol Ther. 2010 Mar;10(3):439-49. doi: 10.1517/14712590903586239.
引用本文的文献
1
Application of Raman Spectroscopy to Dynamic Binding Capacity Analysis.拉曼光谱在动态结合容量分析中的应用。
Appl Spectrosc. 2023 Dec;77(12):1393-1400. doi: 10.1177/00037028231210293. Epub 2023 Nov 1.
2
Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab.用于治疗多发性硬化症的抗CD20药物：聚焦奥瑞珠单抗和奥法妥木单抗。
Brain Sci. 2020 Oct 20;10(10):758. doi: 10.3390/brainsci10100758.
3
Determination of antibodies in everyday rheumatological practice.日常风湿病学实践中抗体的测定。
Reumatologia. 2019;57(2):91-99. doi: 10.5114/reum.2019.84814. Epub 2019 Apr 29.
本文引用的文献
1
Chronic Lymphocytic Leukemia: Current Concepts.慢性淋巴细胞白血病：当前概念
Anticancer Res. 2015 Oct;35(10):5149-65.
2
Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.慢性淋巴细胞白血病：2015 年诊断、风险分层和治疗更新。
Am J Hematol. 2015 May;90(5):446-60. doi: 10.1002/ajh.23979.
3
Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia.奥法木单抗及其在慢性淋巴细胞白血病中作为免疫疗法的作用。
Haematologica. 2015 Apr;100(4):411-4. doi: 10.3324/haematol.2015.124107.
4
Back to the future: oral targeted therapy for RA and other autoimmune diseases.回到未来：RA 和其他自身免疫性疾病的口腔靶向治疗。
Nat Rev Rheumatol. 2013 Mar;9(3):173-82. doi: 10.1038/nrrheum.2013.7. Epub 2013 Feb 19.
5
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.美国食品和药物管理局批准：奥法妥木单抗用于治疗对氟达拉滨和阿仑单抗耐药的慢性淋巴细胞白血病患者。
Clin Cancer Res. 2010 Sep 1;16(17):4331-8. doi: 10.1158/1078-0432.CCR-10-0570. Epub 2010 Jul 2.
6
Chronic lymphocytic leukaemia.慢性淋巴细胞白血病
Lancet. 2008 Mar 22;371(9617):1017-29. doi: 10.1016/S0140-6736(08)60456-0.
7
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.慢性淋巴细胞白血病诊断与治疗指南：慢性淋巴细胞白血病国际研讨会报告，更新美国国立癌症研究所工作组1996年指南
Blood. 2008 Jun 15;111(12):5446-56. doi: 10.1182/blood-2007-06-093906. Epub 2008 Jan 23.
8
Chronic lymphocytic leukemia: diagnosis and treatment.慢性淋巴细胞白血病：诊断与治疗
Mayo Clin Proc. 2006 Aug;81(8):1105-29. doi: 10.4065/81.8.1105.
9
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis.一项基于多变量生存分析得出的慢性淋巴细胞白血病新预后分类。
Cancer. 1981 Jul 1;48(1):198-206. doi: 10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v.
Zotero 插件